» Articles » PMID: 18383837

Overexpression of the Mitotic Spindle Assembly Checkpoint Genes HBUB1, HBUBR1 and HMAD2 in Thyroid Carcinomas with Aggressive Nature

Overview
Journal Anticancer Res
Specialty Oncology
Date 2008 Apr 4
PMID 18383837
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The mitotic spindle assembly checkpoint (MSAC) genes are responsible for preventing chromosome missegregation. MSAC gene expressions have been reported to be associated with tumor cell proliferation or unfavorable cancer behavior. The present study was conducted to preliminary investigate the MSAC gene expressions in thyroid neoplasms.

Materials And Methods: Expression levels of MSAC genes (hBUB1, hBUBR1, hBUB3 and hMAD2) were evaluated in 9 follicular thyroid adenomas (FAs), 9 follicular thyroid carcinomas (FTCs), 21 papillary thyroid carcinomas (PTCs), 5 anaplastic (undifferentiated) thyroid carcinomas (ATCs) and 3 adjacent normal thyroid tissues (NTs) by real-time quantitative RT-PCR. These gene expressions were compared between undifferentiated thyroid carcinomas (ATCs) and differentiated thyroid carcinomas (DTCs) and between advanced DTCs and non-advanced DTCs. DTCs included PTCs and FTCs. Advanced DTCs were defined as carcinoma with aggressive nature such as extrathyroid extension, distant metastasis, recurrence or death from the disease.

Results: MSAC gene expressions varied in different thyroid tumors and fell in the order of ATC, DTC (PTC and FTC), FA and NT Carcinomas had higher expression compared to adenoma or normal tissue. hBUB1, hBUBR1 and hMAD2 expressions in ATCs were significantly higher than those in DTCs (p<0.005). hBUBR1 and hMAD2 expressions in advanced DTCs were significantly higher than those in non-advanced DTCs (p<0.05).

Conclusion: The MSAC genes were overexpressed in thyroid carcinomas with aggressive nature. Further studies are required to clarify the relationship between the MSAC gene expressions and thyroid cancer behavior.

Citing Articles

BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.

Jin T, Ding L, Chen J, Zou X, Xu T, Xuan Z J Cell Mol Med. 2024; 28(7):e18182.

PMID: 38498903 PMC: 10948175. DOI: 10.1111/jcmm.18182.


The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.

Allegri L, Baldan F, Roy S, Aube J, Russo D, Filetti S Sci Rep. 2019; 9(1):7374.

PMID: 31089242 PMC: 6517587. DOI: 10.1038/s41598-019-43894-0.


Development of a risk scoring system for patients with papillary thyroid cancer.

Pak K, Kim Y, Suh S, Goh T, Jeong D, Kim S J Cell Mol Med. 2019; 23(4):3010-3015.

PMID: 30729678 PMC: 6433682. DOI: 10.1111/jcmm.14208.


Aneuploidy: Cancer strength or vulnerability?.

Simonetti G, Bruno S, Padella A, Tenti E, Martinelli G Int J Cancer. 2018; 144(1):8-25.

PMID: 29981145 PMC: 6587540. DOI: 10.1002/ijc.31718.


Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.

Yang L, Feng S, Yang Y Cancer Gene Ther. 2016; 23(12):439-445.

PMID: 27857060 DOI: 10.1038/cgt.2016.64.